期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

膀胱癌免疫治疗研究进展 被引量：1

Advances in immunotherapy for bladder cancer
原文传递
导出
摘要 目前膀胱癌的治疗以手术切除和放疗、化疗为主,但均无法取得理想的效果。近年来新兴的免疫治疗被寄予了厚望。本文就膀胱癌的免疫治疗最新进展作一综述。 The conventional treatments for bladder cancer, including surgery, chemotherapy and radiotherapy, are high- ly invasive and bring about lots of side effects. Immunotherapy has become a promising strategy for the treatment of malig- nant tumors. This review presents the research advances in immunotherapy of bladder cancer.
作者 赵纪宇 陈立军
机构地区 军事医学科学院附属医院泌尿外科
出处 《军事医学科学院院刊》 CSCD 北大核心 2009年第4期395-397,共3页 Bulletin of the Academy of Military Medical Sciences
关键词 膀胱癌 免疫治疗 bladder cancer immunotherapy
分类号 R737.14 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献24

  • 1林荣凯,黄宗海,苏国强,柯志勇,陈建雄,周俊杰.血管内皮生长因子受体启动子驱动重组腺病毒双自杀基因系统选择性杀伤大肠癌细胞[J].第一军医大学学报,2005,25(5):524-527. 被引量：5
  • 2陈小祥,吴强.HSV-tk基因联合其他疗法治疗肿瘤进展[J].临床肿瘤学杂志,2005,10(6):667-669. 被引量：1
  • 3谭万龙,谢毅,吴元东,朱文辉,郑少斌.腺病毒介导融合双自杀基因治疗膀胱癌[J].南方医科大学学报,2006,26(5):594-597. 被引量：13
  • 4尹心宝,黄健.浅表型膀胱癌的生物治疗[J].现代临床医学生物工程学杂志,2006,12(2):219-222. 被引量：3
  • 5O'Reilly MS, Boehm T, Shing Y, et al. Endostatin:an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88:277 -285.
  • 6Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol, 2003,21:223-231.
  • 7Subramanian IV, Ghebre R, Ramakrishnan S. Adeno-associated vires-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther, 2005, 12: 30-38.
  • 8Folkman J. Role of angiogenesis in tumor growth and metastasis.Semin Oncol, 2002, 29: 15-18.
  • 9Zimmem PE, Laub D, Leach GE. Fluorescein angiography of the bladder : technique and relevance to bladder cancer and interstitial cystitis patients. J Urol, 1995, 154:62-65.
  • 10Dickinson A J, Fox SB, Persad RA, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol, 1994,74:762-766.

共引文献8

同被引文献18

  • 1Society AC. Cancer facts & figures 2011. Atlanta: American Cancer Society, 2011.
  • 2Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol, 2007, 25:260-268.
  • 3Ammirante M, Luo JL, Grivennikov S, et al. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature, 2010, 464:302-305.
  • 4Haybaeck J, Zeller N, Wolf M J, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell, 2009,16:295-308.
  • 5Lukashev M, LePage D, Wilson C, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res, 2006, 66:9617-9624.
  • 6Zhou P, Fang X, McNally BA, et al. Targeting lymphotoxin- mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc Natl Acad Sci U S A, 2009, 106: 17134-17139.
  • 7Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev, 2008, 223:202-220.
  • 8Dobrovolskaia MA, Kozlov SV. Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curt Cancer Drug Targets, 2005, 5:325-344.
  • 9Dhawan P, Su Y, Thu YM, et al. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mcdiated transcription in melanoma cells. J Biol Chem, 2008, 283 : 15399-15408.
  • 10Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer:short-term friend, long-term foe. Clin Cancer Res, 2009, 15:425430.

引证文献1

二级引证文献3

军事医学科学院院刊
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部